The top 10 pipeline blowups, setbacks and snafus for H1 2019
These days, when I start writing up a half year’s supply of the top snafus in drug R&D, I start by searching the archives on Alzheimer’s. So much has gone so bad about this field for so long that it has become a regular and reliable player in the area of research setbacks.
That’s a trend with legs.
I usually get tagged with some accusation of schadenfreude when it comes to this series — in one of the lighter frays offered on Twitter. In fact, if you look closely you’ll find valuable lessons included for every R&D exec and investor who likes to watch the field — if they care to learn. But while the education can be had for free, it still amazes me how raw and unexpected the failure is when it does come.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 117,800+ biopharma pros reading Endpoints daily — and it's free.